|
|
|
| |
Thrombotargets has developed and adapted to High Throughput Screening, a new family of biological assays capable to quantify simultaneously clot formation and clot lysis (HemostaScreen), total antioxidant capacity (OxidantScreen) and low-density lipoprotein modification (AtheroScreen). With these proven proprietary new HTS Platforms ( ), Thrombotargets is creating a continuously novel and promising pipeline of drug candidates.
|
|
|
|
|
|
|
Our pipeline is comprised of innovative drug candidates in the fields of Hemostasis and Thrombosis. Some of these compounds, as our recently Orphan Drug Designated TT-103MH topical antihemorrhagic recombinant protein, are available for licensing out. We also have new anticoagulants, antifibrinolytics, antiplatelet agents, and are working on innovative gene therapies for the treatment of coagulation disorders ( Hemophilia, von Willebrand disease, etc).
In ex-vivo human studies using non-anticoagulated blood TT-103MH is able to reduce blood coagulation time in healthy subjects and Haemophilic patients up to 95% (4.5 ± 0.5 minutes to 0.2 ± 0.03 minutes) and 90% (18 ± 1.2 minutes to 1.8 ± 0.3 minutes), respectively. The same potent procoagulant effects were observed in heparinized plasmas and from patients with coagulation factor deficiencies (Factor V, VII, VIII, IX, X, XI, and XII).
Innovative drug discovery and development group of biotech companies developing new medicines based on advances in recombinant DNA and molecular biology and small molecule drug technologies. The programs leverage the company hemostasis expertise and are focused on inherited and acquired Hemorrhagic and Thrombotic disorders.
The topical antihemorrhage drug TT-103MH will arrive at clinical phase I at the beginning of 2008. It's a human recombinant protein for bleeding treatment in healthy subjects, hemophilia A, B, and C, factor VII deficiency, Von Willebrand disease, congenital platelet disorders and hemorrhages induced by anticoagulant and antiplatelet therapies.
|
|
|
|
